AKBA (Akebia Therapeutics) Research & Development: $67.4 Mil (TTM As of Mar. 2026)


AKBA Akebia Therapeutics Inc AKBA
49 GF Score
Price $1.14
GF Value $1.31
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Akebia Therapeutics Research & Development?

Akebia Therapeutics AKBA +10.14% 49 Research & Development is $67.4 Mil as of Mar. 2026. GuruFocus rates AKBA with a GF Score™ of 49/100 and a GF Value™ of $1.31 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Akebia Therapeutics's Research & Development for the three months ended in Mar. 2026 was $14.8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $67.4 Mil.

Akebia Therapeutics  (NAS:AKBA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Akebia Therapeutics Research & Development Related Terms

Akebia Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Research & Development Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 147.85 129.99 63.08 37.65 62.36

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.75 11.01 14.94 26.65 14.81
AKBA
49GF Score
Akebia Therapeutics Inc AKBA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $67.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $67.4 Mil mean?
Akebia Therapeutics (AKBA) has a Research & Development of $67.4 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Research & Development too high?
Akebia Therapeutics' current Research & Development is $67.4 Mil. Overall, Akebia Therapeutics has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Research & Development compare to TKNO and ORGO?
Akebia Therapeutics' Research & Development of $67.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Research & Development is $67.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (AKBA) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.31, compared to a current price of $1.14 — trading 13% below its estimated fair value. The current Research & Development is $67.4 Mil. Akebia Therapeutics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Akebia Therapeutics (AKBA), the current Research & Development is $67.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (AKBA) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of $1.14 is trading 13% below its estimated GF Value™ of $1.31. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for AKBA:

  • Research & Development: $67.4 Mil
  • GF Value™: $1.31 vs. price of $1.14 (13% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the AKBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AX9:Germany
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
49GF Score

Get the complete analysis for AKBA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.14
Price
$1.31
GF Value